(Alliance News) - Hemogenyx Pharmaceuticals PLC on Friday said a third patient has been successfully treated under its phase one trial of its CAR-T cell therapy, HG-CT-1, for relapsed or refractory ...

Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named "TBS-2025;" planning to initiate a Phase 2 trial in relapsed/refractory ...

Third Patient Treated with HG-CT-1 CAR-T Therapy and Completion of First Adult Dose Cohort LONDON, UNITED KINGDOM / ACCESS ...

Amir Fathi, MD, leukemia specialist at Massachusetts General Hospital, discusses the importance of advocacy by both patients ...

"Schrödinger ends development of blood cancer drug after patient deaths" was originally created and published by Clinical ...

Schrödinger Inc (NASDAQ:SDGR) shares dropped 13.7% following the company’s announcement that it is discontinuing development ...

Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute ...

Schrödinger is abandoning its CDC7 inhibitor after the therapy was linked to the deaths of two patients in a phase 1 leukemia trial. The biotech had been evaluating the asset, dubbed SGR-2921, in an ...

Schrodinger discontinued its study of a potential treatment for acute myeloid leukemia or high-risk myelodysplastic syndromes, citing patient deaths linked to the treatment.

GAAP EPS was $(0.49) for Q2 2025, missing analyst estimates by 22.3%. Moleculin Biotech (NASDAQ:MBRX), a clinical-stage pharmaceutical developer focused on oncology, released its second quarter 2025 ...

Researchers sought to determine whether elderly, fit patients with AML would respond to therapy with venetoclax plus modified intensive chemotherapy.

There's light at the end of the tunnel for Kendall Schara in her fight against Acute Myeloid Leukemia, after her sister Elle ...